1. Introduction
Patients with ulcerative colitis (UC) are at increased risk of developing colorectal cancer. This risk increased mainly with longer duration of colitis, greater anatomic extent, and/or association to primary sclerosing cholangitis (PSC). Recent work highlighted also the carcinogenetic role of long-standing – despite if mild or moderate – mucosal inflammation, bringing an additional argument to support the growing concept of mucosal healing as the final target of current and future treatments (Lichtenstein & Rutgeerts, 2010).
Until now, repeated colonoscopic surveillance with biopsies targeted on visible lesions associated to multiple random biopsies in endoscopically normal-appearing mucosa, remains the major way to detect mucosal dysplasia (a precancerous lesion), thereby decreasing colitis-associated cancer (CAC) mortality in UC patients. Colorectal cancer chemoprevention is a second promising strategy to reduce CAC risk in this patients’ population. In particular, most of the available epidemiological data indicate a preventive role for 5-aminosalicylic acid derivatives (5-ASA), despite recent work suggested also a protective role for purine derivatives. Although the main mechanisms by which 5-ASA may reduce CAC risk is not exactly known and remains controversial, some interesting hypothesis have emerged, resulting from fundamental research in molecular biology and pharmacology. This increased understanding of the putative pathway(s) by which 5-ASA may interfere with CAC development appears also as the starting point for optimising 5-ASA derivatives or identifying new compounds acting more specifically and/or being more efficient in preventing neoplastic transformation of the colonic epithelium in UC patients. These different points will be addressed more precisely in the three next parts.
2. Frequency of colorectal cancer risk in ulcerative colitis and risk factors
Ulcerative colitis is a worldwide distributed inflammatory bowel disease (IBD). In a recent review, Cosnes et al., reported that in the West, its incidence and prevalence has increased in the past 50 years, respectively up to 8-14/105 and 120-200/105 persons (Cosnes et al., 2011).
2.1. Frequency of colorectal cancer risk in ulcerative colitis
Compared to the general population, patients with UC have an increased risk to develop colorectal cancer (Kulaylat & Dayton, 2010; Viennot et al., 2009). Early data by Ransohoff estimate the risk of CAC at 0.5% per year after 10 years of UC, and 1.0% per year after 20 years of disease (Ransohoff, 1988). Later, a meta-analysis by Eaden et al. reviewing 116 studies representing a total of 54,478 UC patients, placed the risk of CAC in UC at 2% at 10 years, 8% at 20 years, and 18% at 30 years (Eaden et al., 2001). However, more recently published results, in particular those reporting general population data (in comparison to studies performed in reference centres), suggest that the risk may probably not be so high as reported earlier. This has been the case in a large population-based study by Bernstein et al. in Canada (Manitoba district), were the CAC risk was estimate to be 2.75 increased (95% CI: 1.91-3.97) (Bernstein et al., 2001). In a large study from Denmark (22,290 person-years), Winter et al. reported a 30-year cumulative probability of CAC in UC of 2.1%, a risk not statistically different than in the general population (Winther et al., 2004). Finally, Rutter et al. reported a cumulative CAC incidence of 2.5% at 20 years, 7.6% at 30 years, and 10.8% after 40 years following disease onset (Rutter et al., 2006). However, this study has been performed in a reference centre. This change in risk magnitude reflects probably a change in clinical practice such as a more often use of surveillance colonoscopy, a more systematic use of chemoprevention, and the fact that in several countries surgery was more commonly used in UC treatment than before the advent and progresses in total colectomy or coloproctectomy with either ileorectal or ileoanal anastomosis. However, the influence of other factors (e.g. environmental factors) cannot be excluded. Taking together 48 studies critically appraised for study population type, person years at risk, disease localisation in Crohn’s disease (CD) and censoring for colectomy, Lutgens et al. found a cumulative risk in all IBD patients in population-based studies of 1%, 2% and 5% after 10, 20 or more than 30 years of disease, with a pooled standardised morbidity ratio (SMR) of 3.6 (95% CI: 3.1-4.1), compared to 1%, 11% and 43%, and a pooled SMR of 8.8 (95% CI: 7.3-11) in reference centres studies ( Lutgens et al., 2008 ). In UC pooled SMR was also higher in reference studies (9.0, 95% CI: 7.4-11.1) compared to 3.7 (95% CI: 3.3-4.3) in population-based studies ( Lutgens et al., 2008 ).
2.2. Factors increasing colorectal cancer risk in ulcerative colitis patients
A number of studies have identified clear risk factors exposing UC patients to CAC risk. Most of these factors are inherent to the disease, although possible genetic factors may contribute to increase this risk. The identification of these factors is of outstanding importance, as it will allow us to better define the patients at high risk, representing the target population for colonoscopic surveillance and chemoprevention.
2.2.1. Age of onset and duration of disease
Patients with disease onset at an early age have been shown to be at higher risk of CAC. For example, Ekbom et al. estimated that patients with UC diagnosed before the age of 15, have a 40% risk of CAC after 35 years of disease onset compared to a 25% risk in patients with UC diagnosed between age 15 and 39 (Ekbom et al., 1990). However, the role of age at UC diagnosis alone remains controversial, as most authors suggest that this increased risk results probably (at least in part) from a longer UC duration. Before 8 to 10 years of UC progression, despite a study by Lutgens et al. reporting early occurring CAC ( Lutgens et al., 2008 ), it is currently assumed that the risk of colorectal cancer is not different than the risk for sporadic colorectal cancer in the general population (Eaden et al., 2001; Rutter et al., 2006; Ekbom et al., 1990). It is only later that it increases by approximately 0.5 to 1% each year, reaching the incidence rates reported in Section 2.1.
2.2.2. Disease extension
Extension of colonic disease is a second really important independent risk factor, CAC occurring principally in UC patients having a history of pancolitis or at least of extended colitis (i.e. colitis beyond the left colonic angle). In these patients, relative risk (RR) is about 14.8 (95% IC: 11.4-18.9) compared to 2.8 (95% IC: 1.6-4.4) in patients with left sided UC and 1.7 (95% CI: 0.8-3.2) when disease is limited to the rectosigmoid. In case of proctitis, CAC risk is virtually not higher than in the general population (Ekbom et al., 1990).
2.2.3. Family history of colorectal cancer
A family history of colorectal cancer increases slightly the CAC risk in UC patients (Nuako et al., 1998; Askling et al., 2001a). By contrast, having a first-degree relative affected by UC does not increase the risk for colorectal cancer among other healthy family members (Askling et al., 2001b).
2.2.4. Presence of backwash ileitis
The presence of reflux (or backwash) ileitis has been suggested by several authors to increase CAC risk (Heuschen et al., 2001). However, it remains controversial as other studies found no relation between backwash ileitis and risk for CAC (Rutter et al., 2006a).
2.2.5. Association with primary sclerosing cholangitis
Until now, the most important risk factor for CAC in UC patients is the presence of concomitant PSC (for review see: Torres et al., 2011), even this association occurs only in a minority of patients. For example, a case-control study performed by Broome et al. reported a cumulative CAC risk of 9% after 10 years, 21% after 20 years and 50% after 25 years in patients having both UC and PSC, compared with 2%, 5% and 10% in patients with only UC (Broome et al., 1995). More recently, Sokol et al. showed a 25-year cumulative rate of CAC of 23.4% in patients suffering both from IBD [n = 75; final diagnosis: 42 UC, 21 CD, 1 indeterminate colitis, 11 unclassified IBD (uIBD)] and PSC, compared to 0% in patients with IBD alone (n = 150; final diagnosis: 80 UC, 43 CD, 3 indeterminate colitis, 5 uIBD) (
2.2.6. Chronic inflammation
The impact of chronic inflammation and CAC has long been a matter of debate. In fact, from a theoretical point of view, increasing evidence supported the hypothesis that chronic inflammation contributes to colon carcinogenesis, in particular by generating a favourable microenvironment for cancer initiation, development, and progression. Increase in mucosal pro-inflammatory cytokine or other inflammatory mediators such as reactive oxygen and nitrogen species, or cyclooxygenase-2 (COX-2)-derived prostaglandins production results in alterations of a large number of molecules such as DNA, RNA, proteins or lipids. For example, they induce the formation of adducts to DNA, generating point mutations in genes like the
2.3. Factors suspected to protect from colitis-associated cancer
2.3.1. Folate supplementation
Several experimental and epidemiologic studies have suggested that low folate concentrations increase the risk to develop sporadic colorectal cancer, probably by inducing DNA strand breaks in the
2.3.2. Ursodeoxycholic acid treatment
Several years ago, ursodeoxycholic acid (UDCA) treatment has been considered as playing a protective role against CAC in patients with both UC and PSC. Harnois et al. found that high-doses of UDCA (13-15 mg/kg body weight/day) increased the 4-year survival of these patients (Harnois et al, 2003). Concerning CAC, Pardi et al, studying 52 patients with UC associated to PSC, reported that UDCA treatment (n = 29 patients, 13-15 mg/kg body weight/day for a median of 42 months) decreased dysplasia or CAC risk compared to placebo (10%
3. Chemoprevention by 5-aminosalicylic acids
3.1. 5-aminosalicylates basic pharmacology
Sulphasalazine is the original 5-aminosalicylate (5-ASA)-containing medication used in UC. Chemically, named salicylazosulphapyridine (SASP), it combines two molecules with different properties, sulfapyridine (SP), which has a bacteriostatic activity, and 5-ASA (or mesalazine), the moiety having the anti-inflammatory properties. These two compounds were linked together by an azo bond (Azadkahn et al., 1982). After an oral intake, only a small portion of SASP is absorbed in the small intestine and the bulk of the sulphasalazine reaches the colon intact, where colonic bacterial azoreductase enzymes cleave the azo bond with the subsequent liberation of SP and 5-ASA. As SP seems to be responsible for most of the SASP side effects, new approaches for delivering only 5-ASA have emerged, either using pro-drugs (olsalazine, balsalazide) or oral mesalazine formulations “protecting” 5-ASA from release, absorption, and metabolism in the stomach and proximal small bowel by delayed release (Asacol®, Salofalk®, Mesasal®, Claversal®) or controlled release mechanisms (Pentasa®) (Chourasia & Jain, 2003; Sandborn & Hanauer, 2003). Free 5-ASA administered orally undergoes rapid and nearly complete absorption from the distal ileum or colon (actually depending on concentration and local pH), followed by extensive metabolism to N-Acetyl-5-ASA (N-Ac-5-ASA) by the N-acetyl-transferase 1 (NAT 1) in intestinal epithelial cells and the liver (Sandborn & Hanauer, 2003). A mixture of free 5-ASA and N-Ac-5-ASA is excreted in the urine (Mardini et al., 1987; Rijk et al., 1988; Vree et al., 2000). Only 5-ASA is therapeutically active, some placebo-controlled trial in UC patients having shown that the N-Ac-5-ASA metabolite is inactive (van Hogezand et al., 1988).
3.2. Clinical data
In a retrospective case-control study comparing 102 UC patients with CAC to 196 cancer-free UC patients, Pinczowski et al. provided the first evidence for a role of aminosalicylates in CAC prevention (Pinczowski et al., 1994). They found an independent chemoprotective effect for sulfasalazine taken for at least 3 months with an odds ratio of 0.38 (95% CI: 0.2-0.69 after adjusting for disease activity) (Pinczowski et al., 1994). In an other retrospective study by Moody et al., the crude proportion of UC patients developing CAC was of 3% in those taking long-term 5-ASA compared to 31% in those who stopped their treatment or had poor compliance with 5-ASA therapy (χ2 = 20.2,
This doubt was reinforced by additional data published during the last 4 years, and clearly brought some confusion into clinicians’ mind concerning the real effect of 5-ASA in CAC prevention, despite they have been considered as protective by several health authorities. Bernstein et al. in a population-based survey in Canada (Manitoba University) among 4,325 UC patients and 4,419 CD patients with colonic disease, found no difference in CAC between patients using 5-ASA for more than 1 or 5 years (OR: 1.02, 95% CI 0.60-1.74 and OR: 1.96, 95% CI 0.84-4.55 respectively), with a similar mean number of 5-ASA prescriptions at 10 vs. 11 (
Unfortunately, it would probably not be possible to conduct a prospective double-blinded, placebo-controlled trial to definitively prove or infirm the chemopreventive role of 5-ASA against CAC; regarding the slow CAC increased risk in the general UC population, such a study needed a too important number of patients and a too long period of surveillance. Cost-effectiveness, as well as its impact on clinical practice to prevent CAC, of such a study seems not realistic and will probably never been performed. Therefore, clinicians have to weight the risk/benefit balance of CAC chemoprevention using 5-ASA, and to consider more attentively other strategies increasing their ability to decrease CAC development and morbidity or mortality in UC (and in general colonic IBD) patients (see Chapter 4.).
3.3. Mechanisms of action
As stated above, despite current controversy, clinical data suggest that 5-aminosalicylates may have antineoplastic and potentially chemopreventive properties. It is hypothesized that 5-aminosalicylates may have roughly similar genetic and molecular targets as nonsteroidal anti-inflammatory drugs (NSAIDs), including interactions with ROS production, with the COX and LOX cascade, with the activation of the transcription factor nuclear factor (NF)-κB-dependent effects, and with the peroxisome proliferator-activated receptor-γ (PPAR-γ)-dependent pathway.
3.3.1. Oxidative stress and DNA damage: role in UC-associated CRC carcinogenesis
Oxidative stress is a common consequence of inflammatory and immune activation. Several experimental data have shown that oxidative stress, by affecting both DNA damage and DNA repair processes, and by activating key genes are involved in several inflammatory and carcinogenetic pathways, contributing particularly to epithelial cells neoplastic transformation (Hussain et al., 2003; Boland et al., 2005). In aerobic cells, reactive oxygen species (ROS) are generated as a byproduct of normal mitochondrial activity. However, inflammation induces an increased mitochondrial oxidative metabolism resulting in an enhanced ROS production [e.g. superoxide anion radical (•O2
-), hydrogen peroxide (H2O2), hydroxyl radical (•OH), as well as nitric oxide (NO)] (Boland et al., 2005). These ROS cause major damage to cellular macromolecules, including DNA alterations. Increased expression of ROS and NO [or NO-synthase (NOS), the enzyme which drives NO production from arginine] has been reported in inflamed mucosa from UC or CD patients (Hussain et al., 2000; Oshitani et al., 1993; Rachmilewitz et al., 1995; Kimura et al., 1998; Hofseth et al., 2003). The role of oxidative stress in CAC development has also been suggested. D’Inca et al. reported increased levels of 8-hydroxydeoxyguanosine (8-OHdG: a mutagen formed by the effect of •OH at the C8 position of deoxyguanosine base) in colonic mucosa in UC patients compared to normal mucosa in healthy controls. Furthermore, 8-OHdG concentrations were higher in UC patients with dysplasia, with longer disease duration, and with clinical and histological activity, and were lower in the rectum, suggesting that the 5-aminosalicylate enemas used by most of the study patients might have had an antioxidant effect (D’Inca et al., 2004). Other evidence supporting the contribution of oxidative stress to colorectal carcinogenesis came from the study by Hussain et al. examining the mutation spectrum of
Numerous reports have suggested that oxidative stress may play a role in colon carcinogenesis. In colon cancer cell lines, ROS such as •O2 -, •OH, hypochlorite anion, and, in particular H2O2 induce frameshift mutations and inactivate the DNA mismatch repair system (Gasche et al., 2001; Chang et al., 2002). Concerning this point, several studies indicate that mesalazine is able to inhibit ROS production and/or their deleterious effects (Allgayer et al., 1992; Allgayer, 2003).
3.3.2. 5-aminosalicylates and cyclooxygenase-2 inhibition
As stated in Section 2.2.6 COX-2 represents an important target in colorectal cancer in general, and CAC in particular. Due to its structural similarity with other COX inhibitors and to the over-expression of COX-2 in inflamed UC colonic mucosa, it has been suggested that 5-ASA chemoprotective properties against CAC were linked to its capacity to inhibit COX-2 activity. However, experimental data remain controversial. In an experimental study published by Stolfi et al., 5-ASA effectively inhibited colon cancer cell line HCT-115 (which expresses constitutively COX-2) proliferation and, in addition, down-regulated COX-2 mRNA and protein expression, and finally decreased prostaglandin E2 production (Stolfi et al., 2008). However, addition of exogenous prostaglandin E2 to cell culture does not reverse 5-ASA’s inhibitory effect on HCT-115 proliferation. Furthermore, Stolfi et al. showed that 5-ASA inhibits proliferation in DLD-1 human colon cancer cell line (which does neither express COX-1, nor COX-2), a result we reproduced recently (unpublished data) (Stolfi et al., 2008). Therefore, inhibition of colon carcinogenesis by 5-ASA appears partially independent of its effects on COX-2.
3.3.3. Peroxisome proliferator-activated receptor-γ activation
Peroxisome proliferator-activated receptor-γ is a nuclear receptor highly expressed in the colonic mucosa. Several studies have demonstrated that its activation both decreased tumour cells proliferation and increased pro-apoptotic activities (Matthiessen et al., 2005; Shimada et al., 2002; ), inhibited aberrant crypt foci formation (Tanaka et al., 2001), and reduced colorectal cancer development (Osawa et al., 2003), presumably through an interaction with the Wnt/β-catenin pathway (Jansson et al., 2005; Lu et al., 2005). Rousseaux et al. have demonstrated that 5-ASA acts like a PPAR-γ ligand (Rousseaux et al., 2005). Performing both
3.3.4. 5-aminosalicylic acid and nuclear factor NF-kappa B
The clinical efficacy of 5-ASA as a chemopreventive drug against CAC may probably also be the result of its inhibition of the pro-inflammatory and pro-oncogenic nuclear factor kappa B (NF-κB). Nuclear factor-κB is a transcription factor controlling the expression of numerous genes implicated both in inflammatory and immune response, and additionally in initiation, development and propagation of colorectal cancer in UC patients. Although few data are available, the key role of NF-κB both in regulating inflammatory/immune response in IBD patients, and its implication in colorectal carcinogenesis, pointed researchers interest towards its role in CAC. In particular, the close link between TNF-α (clearly recognized as a pro-carcinogen in CAC) and NF-κB, suggested that NF-κB probably contributes to CAC onset and development. Until now, this has only been shown in an animal study (Onizawa et al., 2009) and suspected from the results published by Popivanova et al. in 2008 (Popivanova et al., 2008; ).
3.3.5. Effects on the Wnt/β-catenin and the epidermal growth factor receptor pathways
Recent studies have hypothesized that 5-ASA may also exert its chemopreventive properties directly, and not only through its actions on mucosal inflammation. Mesalamine has been reported to decrease the activity of the wingless and integration site growth factor (Wnt)/β-catenin pathway [which is constitutively activated in up to 80% of sporadic colorectal cancers due to somatic mutation of the
5-aminosalicylic acid has also been reported to inhibit epidermal growth factor receptor (EGFR) pathway. This pathway has been shown to be highly activated in colorectal cancer, and is one of the targets of currently used biotherapies in sporadic colorectal cancer (cetuximab, Erbitux®). In CAC, over-expression of EGFR is frequent (Svrcek et al., 2007), and
4. Conclusion and current clinical recommendations
Colitis-associated cancer prevention in UC (and colonic CD) remains a controversial subject. Following initial data reporting an important increase in colorectal cancer in UC patients, more recent studies performed not only in reference centres but also considering the general UC patients population, reported a CAC risk probably lower than the risk reported in earlier work. In addition, despite numerous (but also often contradictory experimental data on 5-ASA effects on colorectal cancer initiation, development and progression) suggesting a protective role of 5-ASA against CAC in UC patients, most of the data are retrospective, some data are contradictory, and a clear conclusion could not been drawn. In addition, it seems unlikely that a prospective, large population-based study to evaluate 5-ASA chemopreventive properties against CAC would be performed, due to its costs, duration, and number of patients needed to participate.
As a conclusion, clinicians should therefore be very cautious but also consider each UC (or colonic CD) patient as a particular case. Nevertheless, in our opinion and despite several uncertainties, the best remains to follow practical guidelines recommended by numerous gastroenterological scientific societies. These guidelines usually propose a systematic chemopreventive use of 5-ASA (usually around 1.8 to 2 g/day) in addition to systematic colonoscopic dysplasia and CAC screening including chromoendoscopy using either indigo carmine or methylene blue.
References
- 1.
Agoff S. N. Brentnall T. A. Crispin D. A. Taylor S. N. Raaka S. Haggitt R. C. Reed M. W. Afonina I. A. Rabinovitch P. S. Stevens A. C. Feng Z. Bronner M. P. 2000 The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. , 157, 3, Septembre 2000737 745 ,0002-9440 - 2.
Allgayer H. 2003 Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease . , 18 (Suppl. 2), September 200310 14 ,0269-2813 - 3.
Allgayer H. Höfer P. Schmidt M. Böhne P. Kruis W. Gugler R. 1992 Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. , 43, 2, January 1992259 262 ,0006-2952 - 4.
Askling J. Dickman P. W. Karlén P. Brostrom O. Lapidus A. Löfberg R. Ekbom A. 2001a Family history as a risk factor for colorectal cancer in inflammatory bowel disease . , 120, 6, May 20011356 1362 ,0016-5085 - 5.
Askling J. Dickman P. W. Karlén P. Brostrom O. Lapidus A. Löfberg R. Ekbom A. 2001b Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. , 357, 9252, January 2001262 266 ,0140-6736 - 6.
Azadkahn A. K. Truelove S. C. Aronson J. K. 1982 The disposition and metabolism of sulphasalasine (salicylazosulphapyridine) in man. , 16, 4, April 1982523 528 ,0306-5251 - 7.
Bernstein C. N. Nugent Z. Blanchard J. F. 2011 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population-based study. , 106, 4, April 2011731 736 ,0002-9266 - 8.
Bernstein C. N. Blanchard J. F. Kliewer E. Wajda A. 2001 Cancer risk in patients with inflammatory bowel disease: a population-based study. , 91, 4, February 2001854 862 ,0008-543X . - 9.
Biasco G. Zannoni U. Paganelli G. M. Santucci R. Gionchetti P. Rivolta G. Miniero R. Pironi L. Calabrese C. Di Febo G. Miglioli M. 1997 Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. , 6, 6, June 1997469 471 ,1055-9965 - 10.
Boland C. R. Luciani M. G. Gasche C. Goel A. 2005 Infection, inflammation, and gastrointestinal cancer. , 54, 9, September 2005,1321 1231 ,0017-5749 - 11.
Bos C. L. Diks S. H. Hardwick J. C. Walburg K. V. Peppelenbosch M. P. Richel D. J. 2006 Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/β-catenin pathway activity. , 27, 12, December 20062371 2382 ,0143-3334 - 12.
Broomé U. Löfberg R. Veress B. Eriksson L. S. 1995 Primary sclerosing cholangitis and ulcerative colitis. Evidence for increased neoplastic potential. , 22, 5, November 19951404 1408 ,0270-9139 - 13.
Cao Y. Pearman A. T. Zimmerman G. A. McIntyre T. M. Prescott M. 2000 Intracellular unesterified arachidonic acid signals apoptosis . , 97, 21, October 200011280 11285 ,0027-8424 - 14.
Chang C. L. Marra G. Chauhan D. P. Ha H. T. Chang D. K. Ricciardiello L. Randolph A. Carethers J. M. Boland C. R. 2002 Oxidative stress inactivates the human DNA mismatch repair system. . Cell Physiology, 283, 1, July 2002,C148 C154 ,0363-6143 - 15.
Chourasia M. K. Jain S. K. 2003 Pharmaceutical approaches to colon targeted drug delivery systems. , 6, 1, January-April 200333 66 ,1482-1826 - 16.
Cosnes J. Gower-Rousseau C. Seksik P. Cortot A. 2011 Epidemiology and natural history of inflammatory bowel diseases . , 140, 6, May 20111785 1794 ,0016-5085 - 17.
D’Inca R. Cardin R. Benazzato L. Angriman I. Martines D. Sturniolo G. C. 2004 Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. , 10, 1, January 200423 27 ,1078-0998 - 18.
Desreumaux P. Ghosh S. 2006 Review article: mode of action and delivery of 5-aminosalicylic acid- new evidence. , 24 Suppl 1, September 20062 9 ,0269-2813 - 19.
Eaden J. Abrams K. Ekbom A. Jackson E. Mayberry J. 2000 Colorectal cancer prevention in ulcerative colitis: a case-control study . , 14, 2, February 2000145 153 ,1078-0998 - 20.
Eaden J. Abrams K. R. Mayberry J. J. 2001 The risk of colorectal cancer in ulcerative colitis: a meta-analysis. , 48, 4, April 2001526 535 ,0017-5749 - 21.
Eaton J. E. Silveira M. G. Pardi D. S. Sinakos E. Kowdley K. V. Luketic V. A. Harrison M. E. McCashland T. Befeler A. S. Harnois D. Jorgensen R. Petz J. Lindor K. D. 2011 High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. , May 2011 (in press),0002-9266 - 22.
Ekbom A. Helmick C. Zack M. Adami H. O. 1990 Ulcerative colitis and colorectal cancer. A population-based study. , 323, 18, November 19901228 1233 ,0028-4793 - 23.
Garrity-Park M. Loftus E. V. Jr. Sandborn W. J. Smyrk T. C. 2011 Myeloperoxydase immunohistochemitry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. , March 2011 (in press),1078-0998 - 24.
Gasche C. Chang C. L. Rhees J. Goel A. Boland C. R. 2001 Oxidative stress increases frameshift mutations in human colorectal cancer cells. , 61, 20, October 20017444 7448 ,0008-5472 - 25.
Gerrits M. M. Chen M. Theeuwes M. van Dekken H. Sikkema M. Steverberd E. W. Lingsma H. F. Siersema P. D. Xia B. Kusters J. G. van der Woude C. J. Kuipers E. J. 2011 Biomarker-based prediction or inflammatory bowel disease-related colorectal cancer: a case-control study. , 34, 2, April 2011107 117 ,2211-3436 - 26.
Giovannucci E. Stampfer M. J. Colditz G. A. Hunter D. J. Fuchs C. Rosner B. A. Speizer F. E. Willett W. C. 1998 Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. , 129, 7, October 1998517 524 ,0003-4819 - 27.
Giovannucci E. Stampfer M. J. Colditz G. A. Rimm E. B. Trichopoulos D. Rosner B. A. Speizer F. E. Willett W. C. 1993 Folate, methionine, and alcohol intake and risk of colorectal adenoma. , 85, 11, June 1993875 884 ,0027-8874 - 28.
Gupta R. B. Harpaz N. Itzkowitz S. Hossain S. Matula S. Kornbluth A. Bodian C. Ullman T. 2007 Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study . , 133, 4, October2007 1099 1105 ,0016-5085 - 29.
Harnois D. M. Angulo P. Jorgensen R. A. Larusso N. F. Lindor K. D. 2001 High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. , 96, 5, May 20011558 1562 ,0002-9266 - 30.
Heuschen U. A. Hinz U. Allemeyer E. H. Stern J. Lucas M. Autschbach F. Herfarth C. Heuschen G. 2001 Backwash ileitis is strongly associated with colorectal cancer in patients with ulcerative colitis. , 120, 4, March 2001841 847 ,0016-5085 - 31.
Hofseth L. J. Saito S. Hussain S. P. Espey M. G. Miranda K. M. Araki Y. Jhappan C. Higashimoto Y. He P. Linke S. P. Quezado M. M. Zurer I. Rotter V. Wink D. A. Appella E. Harris C. C. 2003 Nitric oxide-induced cellular stress and p53 activation in chronic inflammation . , 100, 1, January 2003, 143-148,0027-8424 - 32.
Hudson J. D. Shoaibi M. A. Maestro R. Carnero A. Hannon G. J. Beach D. H. 1999 A proinflammatory cytokine inhibits p53 tumor suppressor activity. , 190, 10, November 1999, 1375-1382,0022-1007 - 33.
Hussain S. P. Amstad P. Raja K. Ambs S. Nagashima M. Bennett W. P. Shields P. G. Ham A. J. Swenberg J. A. Marrogi A. J. Harris C. C. 2000 Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. , 60, 13, July 2000, 3333-3337,0008-5472 - 34.
Hussain S. P. Hofseth L. J. Harris C. C. 2003 Radical causes of cancer. Cancer, 3, 4, April 2003276 285 ,1474-175X . - 35.
Jansson E. A. Are A. Greicius G. Kuo I. C. Kelly D. Arulampalam V. Pettersson S. 2005 The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. , 102, 5, February 20051460 1465 ,0027-8424 - 36.
Kim Y. I. Pogribny I. P. Basnakian A. G. Miller J. W. Selhub J. James S. J. Mason J. B. 1997 Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. , 65, 1, January 1997, 46-52,0002-9165 - 37.
Kimura H. Hokari R. Miura S. Shigematsu T. Hirokawa M. Akiba Y. Kurose I. Higuchi H. Fujimori H. Tsuzuki Y. Serizawa H. Ishii H. 1998 Induced expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. , 42, 2, February 1998180 187 ,0017-5749 - 38.
Kulaylat M. N. Dayton M. T. 2010 Ulcerative colitis and cancer . , 15, 8, June 2010706 712 ,0022-4790 - 39.
Lashner B. A. 1993 Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. , 119, 9, September 1993549 554 ,0171-5216 - 40.
Lashner B. A. Heudenreich P. A. Su G. L. Kane S. V. Hanauer S. B. 1989 Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis . , 97, 2, August 1989255 259 ,0016-5085 - 41.
Lashner B. A. Provencher K. S. Seidner D. L. Knesebeck A. Brzezinski A. 1997 The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. , 112, 1, January 199729 32 ,0016-5085 - 42.
Laurent C. Svrcek M. Flejou J. F. Chenard M. P. Duclos B. Freund J. N. Reimund J. M. 2011 Immunohistochemical expression of CDX2, ß-catenin and TP53 in inflammatory bowel disease-associated colorectal cancer. , 17, 1, January 2011232 240 ,1078-0998 - 43.
Lichtenstein G. R. Rutgeerts P. 2010 Importance of mucosal healing in ulcerative colitis . , 16, 2, February 2010338 346 ,1078-0998 - 44.
Loftus E. V. Jr. Aguilar H. I. Sandborn W. J. Tremaine W. J. Krom R. A. Zinsmeister A. R. Graziadai I. W. Wiesner R. H. 1998 Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation . , 27, 3, March 1998685 690 ,0270-9139 - 45.
Lu D. Cottam H. B. Corr M. Carson D. A. 2005 Repression of beta-catenin function in malignant cells by nonsteroidal anti-inflammatory drugs. , 102, 51, December 200518567 18571 ,0027-8424 - 46.
Lutgens M. W. van der Heijden G. J. Vleggaar F. D. Oldenburg B. 2008 A comprehensive meta-analysis of the risk of colorectal carcinoma in ulcerative colitis and Crohn’s disease. , 57 (Suppl II), A131,0017-5749 - 47.
Lutgens M. W. M. D. Vleggaar F. P. Schipper M. E. I. Stokkers P. C. F. van der Woude C. J. Hommes D. W. de Jong D. J. Dijkstra G. van Bodegraven A. A. Oldenburg B. Samsom M. 2008 High frequency of early colorectal cancer in inflammatory bowel disease . , 57, 9, September 20081246 1251 ,0017-5749 - 48.
Mardini H. A. Lindsay D. C. Deighton C. M. Record C. O. 1987 Effect of polymer coating on faecal recovery of ingested 5-aminosalicylic acid in patients with ulcerative colitis. , 28, 9, September 19871084 1089 ,0017-5749 - 49.
Matthissen M. W. Pedersen G. Albrektsen T. Adamsen S. Fleckner J. Brynskov J. 2005 Peroxisome proliferator-activated receptor expression and activation in normal colonic epithelial cells and tubular adenomas. , 40, 2, February 2005198 205 ,0036-5521 - 50.
Moghal N. Sternberg P. W. 1999 Multiple positive and negative regulators of signaling by the EGF-receptor. , 11, 2, April 1999190 196 ,0955-0674 - 51.
Monteleone G. Franchi L. Fina D. Carusao R. Vavassori P. Monteleone I. Calabrese E. Naccari G. C. Bellinvia S. Testi R. Pallone F. 2006 Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. , 13, 2, February 2006202 211 ,1350-9047 - 52.
Moody G. A. Jayanthi V. Probert C. S. Mac Kay H. Mayberry J. F. 1996 Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. , 8, 12, December 19961179 1183 ,0954-691X . - 53.
Nuako K. W. Ahlquist D. A. Mahoney D. W. Schaid D. J. Siems D. M. Lindor N. M. 1998 Familial predisposition for colorectal cancer in ulcerative colitis: a case-control study , 115, 5, November 19981079 1083 ,0016-5085 - 54.
Onizawa M. Nagaishi T. Kanai T. Nagano K. Oshima S. Nemoto Y. Yoshioka A. Totsuka T. Okamoto R. Nakamura T. Sakamoto N. Tsuchiya K. Aoki K. Ohya K. Yagita H. Watanabe M. 2009 Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. . Gastrointestinal and Liver Physiology, 296, 4, April 2009,G850 859 ,0193-1857 - 55.
Osawa E. Nakajima A. Wada K. Ishimine S. Fujisawa N. Kawamori T. Matsuhashi N. Kadowaki T. Ochiai M. Sekihara H. Nakagama H. 2003 Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. , 124, 2, February 2002361 367 ,0016-5085 - 56.
Oshitani N. Kitano A. Okabe H. Nakamura S. Matsumoto T. Kobayashi K. 1993 Location of superoxide anion generation in human colonic mucosa obtained by biopsy. , 35, 7, July 1993284 285 ,0017-5749 - 57.
Pardi D. S. Loftus E. V. Jr. Kremers W. K. Keach J. Lindor K. D. 2003 Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. , 124, 4, April 2003889 893 ,0016-5085 - 58.
Phelip J. M. Ducros V. Faucheron J. L. Flourié B. Roblin X. 2008 Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease . , 14, 2, February 2008242 248 ,1078-0998 - 59.
Pinczowski D. Ekbom A. Baron J. Yuen J. Adami H. O. 1994 Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. , 107, 1, July1994 117 120 ,0016-5085 - 60.
Popivanova B. K. Kitamura K. Wu Y. Kondo K. Kagava T. Kaneko S. Oshima M. Fujii C. Mukaida M. 2008 Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. , 118, 2, February 2008560 570 ,0021-9738 - 61.
Rachmilewitz D. Stamler J. S. Bachwich D. Karmeli F. Ackerman Z. Podolsky D. K. 1995 Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. , 36, 5, May 1995718 723 ,0017-5749 - 62.
Ransohoff D. F. 1988 Colon cancer in ulcerative colitis. , 94, 4, April 19881089 1091 ,0016-5085 - 63.
Rijk M. C. van Schaik A. van Tongeren J. H. 1988 Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. , 23, 1, January 1988107 112 ,0036-5521 - 64.
Roessner A. Kuester D. Malfertheiner P. Schneider-Stock R. 2008 Oxidative stress in ulcerative colitis-associated carcinogenesis . , 204, 7, June 2008511 524 ,0344-0338 - 65.
Rousseaux C. Lefebvre B. Dubuquoy L. Lefebvre P. Romano O. Auwerx J. Metzger D. Wahli W. Desvergne B. Naccari G. C. Chavatte P. Farce A. Bulois P. Cortot A. Colombel J. F. Desreumaux P. 2005 Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. , 201, 8, April 20051205 1215 ,0022-1007 - 66.
Rutter M. D. Saunders B. P. Wilkinson K. H. Rumbles S. Schofield G. Kamm M. Williams C. B. Price A. B. Talbot I. C. Forbes A. 2004a Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. , 53, 12, December 20041813 1816 ,0017-5749 - 67.
Rutter M. Saunders B. Wilkinson K. Rumbles S. Shofield G. Kamm M. Williams C. Price A. Talbot I. Forbes A. 2004b Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 126, 2, February 2004451 459 ,0016-5085 - 68.
Rutter M. D. Saunders P. P. Wilkinson K. H. Rumbles S. Schofield G. Kamm M. Williams C. B. Price A. B. Talbot I. C. Forbes A. 2006 Thirty years analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis. , 130, 4, April 20061030 1038 ,0016-5085 - 69.
Sandborn W. J. Hanauer S. B. 2003 Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. , 17, 1, January 200329 42 ,1078-0998 - 70.
Shimada T. Kojima K. Yoshiura K. Hiraishi H. Terano A. 2002 Characteristics of the peroxisome proliferator receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells . , 50, 5, May 2002658 664 ,0017-5749 - 71.
Sjöqvist U. Tribukait B. Ost A. Einarsson C. Oxelmark L. Löfberg L. 2004 Ursodeoxycholic acid treatment in IBD patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. , 24, 5B, September-October 20043121 3127 ,0250-7005 - 72.
Sokol H. Cosnes J. Chazouillieres O. Beaugerie L. Tiret E. Poupon R. Seksik P. 2008 Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis . , 14, 22, June 20083497 3503 ,1007-9327 - 73.
Stolfi C. Fina D. Caruso R. Caprioli F. Sarra M. Fantini M. C. Rizzo A. Pallone F. Monteleone G. 2008 Cyclooxygenase-dependent and-independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. , 75, 3, February 2008668 676 ,0006-2952 - 74.
Svrcek M. Cosnes J. Tiret E. Bennis M. Park Y. Flejou J. F. 2007 Expression of epidermal growth factor receptor (EGFR) is frequent in inflammatory bowel disease (IBD)-associated intestinal cancer. , 450, 2, February 2007243 244 ,0945-6317 - 75.
Tanaka T. Kohno H. Yoshitani S. Takashima S. Okumura A. Murakami A. Hosokawa M. 2001 Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. , 61, 6, March 20012424 2428 ,0008-5472 - 76.
Terdiman J. P. Steinbuch M. Blumentals W. A. Ullman T. A. Rubin T. D. 2007 5-aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel diseases . ,13 367 371 ,1078-0998 - 77.
Torres J. de Chambrun G. P. Itzkowitz S. Sachar D. B. Colombel J. F. 2011 Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. , June 2011 (in press),0269-2813 - 78.
Van Hogezand R. A. van Hees P. A. van Gorp J. P. van Lier H. J. Bakker J. H. Wesseling P. van Haelst U. J. van Tongeren J. H. 1988 Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. , 2, 1, February 198833 40 ,1078-0998 - 79.
van Staa T. P. Card T. Logan R. F. Leufkens H. G. M. 2005 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. , 54, 11, November 20051573 1578 ,0017-5749 - 80.
Velayos F. S. Loftus E. V. Jr. Jess T. Harmsen W. S. Bida J. Zinsmeister A. R. Tremaine W. J. Sandborn W. J. 2006 Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study . , 130, 7, June 20061941 1949 ,0016-5085 - 81.
Velayos F. S. Terdiman J. P. Walsh J. M. 2005 Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies . , 100, 6, June 20051354 1356 ,0002-9266 - 82.
Viennot S. Deleporte A. Moussata D. Nancey S. Flourié B. Reimund J. M. 2009 Colon cancer in inflammatory bowel disease: recent trends, questions and answers . , 33 Suppl 3, June 2009,S190 201 ,0399-8320 - 83.
Vree T. B. Dammers E. Exler P. S. Sorgel F. Bondesen S. Maes R. A. 2000 Liver and gut mucosa acetylation of mesalazine in healthy volunteers. , 38, 11, November 2000514 522 ,0946-1965 - 84.
Winther K. V. Jess T. Langholz E. Munkholm P. Binder V. 2004 Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County . , 2, 12, December 20041088 1095 ,1542-3565 - 85.
Wolf J. A. Rybicki L. A. Lashner B. A. 2005 The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary scleosing cholangitis. , 22, 9, November 2005783 788 ,1078-0998 - 86.
Yakut M. Ustün Y. Kabaçam G. Soykan I. 2010 Serim vitamin B12 and folate status in patients with inflammatory bowel disease. , 21, 4, August 2010,0953-6205